134) In this study, we found significantly increased Gal-3 serum levels in patients with AD compared to control participants (P=.017). |
PMID:23823143 DOI:10.1177/1533317513495107 |
2015 American journal of Alzheimer's disease and other dementias |
* Elevated Galectin-3 Levels in the Serum of Patients With Alzheimer's Disease. |
- Alzheimer's disease (AD) is a neurodegenerative disorder of the central nervous system. Galectin-3 (Gal-3) is characterized by a conserved sequence within the carbohydrate recognition domain. The effect of Gal-3 in AD is presently unknown. In this study, we found significantly increased Gal-3 serum levels in patients with AD compared to control participants (P=.017). There was no significant difference between patients with mild cognitive impairment (MCI) and healthy controls (P=.143) or between patients with AD and MCI (P=.688). The degree of cognitive impairment, as measured by the Mini-Mental Status Examination score, was found to have a significant correlation with the Gal-3 serum levels in all patients and healthy controls. These data suggest that Gal-3 potentially plays a role in the neuropathogenesis of AD. The Gal-3 found in serum could be a potential candidate for a biomarker panel for AD diagnosis. |
(1)88 higher | (13)8 improved | (25)3 (P<0.05) | (39)2 impaired |
(2)43 lower | (14)6 correlated | (27)3 affect | (40)2 increases |
(3)39 increased | (15)6 elevated | (28)3 better | (41)2 induced |
(4)35 reduced | (16)6 fewer | (29)3 increase | (42)2 larger |
(5)32 associated | (17)6 less | (30)3 worse | (43)2 predicted |
(6)17 decreased | (18)5 enhanced | (31)2 (P | (44)2 reduce |
(7)13 in | (19)5 inhibited | (32)2 (p | (45)2 shorter |
(8)13 more | (20)4 affected | (34)2 altered | (46)2 smaller |
(9)10 greater | (21)4 attenuated | (35)2 by | (47)2 suppressed |
(10)10 related | (22)4 between | (36)2 compared | (48)2 to |
(11)9 *null* | (23)4 from | (37)2 decreased, | |
(12)9 different | (24)4 the | (38)2 differed |
add keyword